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Transcutaneous Electrical Nerve Stimulation to
Improve Female Sexual Dysfunction
Symptoms: A Pilot Study
Lauren L. Zimmerman, MS*† ; Priyanka Gupta, MD‡;
Florence O’Gara, BSN, MSW§; Nicholas B. Langhals, PhD¶1 ;
Mitchell B. Berger, MD, PhD**†† ; Tim M. Bruns, PhD*†
Objectives: To perform a pilot study using transcutaneous electrical nerve stimulation (TENS) on the dorsal genital nerve and
the posterior tibial nerve for improving symptoms of female sexual dysfunction (FSD) in women without bladder problems.
We hypothesize that this therapy will be effective at improving genital arousal deficits.
Materials and Methods: Nine women with general FSD completed the study. Subjects received 12 sessions of transcutaneous
dorsal genital nerve stimulation (DGNS; n = 6) or posterior tibial nerve stimulation (PTNS; n = 3). Stimulation was delivered for
30 min at 20 Hz. Sexual functioning was evaluated with the female sexual functioning index (FSFI), and surveys were also
given on general health, urological functioning, and the Patients’ Global Impression of Change (PGIC) after treatment. Surveys
were given before treatment (baseline), after 6 and 12 weeks of treatment, and 6 weeks after the completion of stimulation
sessions.
Results: The average total FSFI score across all subjects significantly increased from 15.3  4.8 at baseline to 20.3  7.8 after
six sessions, 21.7  7.5 after 12 sessions, and 21.3  7.1 at study completion (p < 0.05 for all time points). Increases were
observed in both DGNS and PTNS subjects. Significant FSFI increases were seen in the subdomains of lubrication, arousal, and
orgasm, each of which is related to genital arousal. Bladder and general health surveys did not change across the study. PGIC
had a significant increase.
Conclusions: This study provides evidence that transcutaneous stimulation of peripheral nerves has the potential to be a valu-
able therapeutic tool for women with FSD.
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INTRODUCTION
Female sexual dysfunction (FSD) affects 40–45% of adult
women and is a difficult condition to diagnose and treat (1,2).
Low genital arousal and poor lubrication affects between 8 and
28% of women and orgasm difficulties affect 16–25% (2,3), and
can be due to underactive neural or vascular activity in the geni-
tals, urological problems, or other pelvic floor dysfunctions (4).
Low sexual desire, or interest, affects 9–39% of women (2,5), and
may be due to hyperactivity in prefrontal areas of the brain (4).
Women are more likely to have FSD as they age, and women
often have more than one form of FSD (2). An active and satisfy-
ing sex life is widely regarded not only as desirable but as a sign
of emotional and physical health. The sexually disinterested
person with arousal difficulties is made to feel deficient, dissatis-
fied, or dysfunctional (6). Medical providers and therapists are
challenged by treatment as there are multiple possible contribu-
tors and different forms of FSD. Hormone therapy can be effective
for genital and desire dysfunctions, but is not recommended for
all individuals and is typically not recommended for long-term
treatment (7). Flibanserin, a recently FDA-approved drug, has
some success in increasing sexual desire but does not impact
genital arousal (8,9). Sildenafil has occasionally been reported to
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improve genital arousal (10), but results are inconsistent and fre-
quently present with mild to moderate side-effects such as head-
aches, flushing, rhinitis, and nausea (11). There is a need for an
effective treatment for women who have genital arousal deficien-
cies without concurrent side-effects.
Peripheral neuromodulation therapies have been implemented for
patients with bladder dysfunction for decades. Sacral neuromodula-
tion (SNM) involves the surgical implantation of a stimulation system,
with an electrode near the S3 sacral foramen delivering continuous
stimulation (12). Dorsal genital nerve stimulation (DGNS) is typically
delivered transcutaneously above the clitoris and lateral to the labia
majora in women (13–15), though percutaneous electrodes may also
be used (16). The dorsal genital nerve is a distal branch of the puden-
dal nerve, which is stimulated centrally with SNM. Percutaneous tibial
nerve stimulation (PTNS) is a treatment where patients receive
30 min of electrical stimulation a week for 12 weeks with periodic
maintenance sessions thereafter (17,18), though benefits have been
observed after as few as six sessions (19). Stimulation is delivered via
a percutaneous needle placed at the tibial nerve near the ankle, but
cutaneous stimulation with transcutaneous electrical nerve stimula-
tion (TENS) electrodes has also shown efficacy in some studies
(20–22). The underlying mechanisms of these neuromodulation
therapies are not well understood, with evidence suggesting inhibi-
tion at spinal and/or supra-spinal levels affecting efferent control
over bladder storage and emptying (19,23).
In clinical studies in which patients received neuromodula-
tion treatment for bladder dysfunction, significant improve-
ments in sexual functioning as evaluated with the Female
Sexual Function Index (FSFI) were noted for SNM (24–27) and
PTNS (28–30) therapies. While bladder dysfunction has a
known negative effect on sexual function (31,32), improve-
ments in sexual functioning were found to be independent
from improvements in bladder functioning (25,30), indicating
that the neuromodulation may have a direct impact on genital
arousal. No studies have evaluated the effects of peripheral
nerve stimulation specifically on patients with FSD without an
underlying urological condition.
The goal of this pilot study was to evaluate weekly skin-surface
TENS of the dorsal genital nerve and the posterior tibial nerve for
improving sexual function in women with FSD and no clinically
diagnosed bladder problems.
METHODS
Approval for this study was obtained from the Michigan
Medicine Institutional Review Board prior to initiation (study
number HUM00101713). Participants were recruited through
Michigan Medicine sexual health practices, gynecology clinics,
and an online University of Michigan health research portal
(umhealthresearch.org). This study was registered at clinicaltrials.
gov under identifier NCT02692417.
In a phone call with a study coordinator, subjects were
screened for study eligibility. All subjects were 18 years or older
cis-gender women, neurologically stable, and sexually active at
least once a month. The short-form FSFI-6 was used to screen for
FSD, with scores below 19 required for inclusion (33). The specific
type or types of FSD that each participant had was not identified
as part of the screening process. Women who were pregnant or
planning pregnancy, had clinically diagnosed bladder dysfunction
or pelvic pain, previous pelvic surgery, experience with electrical
stimulation for bladder or sexual problems, recent use of TENS on
their pelvis, back, or legs, had an implanted pacemaker, defibrilla-
tor, spinal cord stimulator, or other nerve stimulator, or were tak-
ing any investigational drug were excluded from the study. All
subjects provided written informed consent. A pregnancy test
was also performed at the first session to confirm nongravidity if
the subjects were premenopausal and had not had a hysterec-
tomy. Menopause status was not specifically tracked across partic-
ipants. The intended sample size of this study was 20 subjects,
with 10 subjects in each study group, similar to other neuromodu-
lation pilot studies (13,14,34). As described below, a smaller sam-
ple size was reached due to challenges in subject recruitment and
retention.
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Figure 1. Study CONSORT flow diagram. [Color figure can be viewed at wileyonlinelibrary.com]
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At the first stimulation session, patients were randomized into
one of two study groups, DGNS or PTNS. Randomization was
accomplished using a random-number table and block size of
two. Allocation assignment was performed using sequentially
numbered, opaque sealed envelopes, which were opened in the
presence of the subjects. Subjects received skin-surface stimula-
tion with a TENS unit (Empi Select, DJO Global, Vista, CA, USA).
Electrodes were 1.25-inch round neurostimulation electrodes
(ValuTrode Fabric CF3200, Axelgaard Manufacturing Co., Ltd.,
Fallbrook, CA, USA). For DGNS participants, each electrode was
placed on either lateral side of the clitoris (15). For PTNS partici-
pants, electrodes were placed just above the medial malleolus
and the ipsilateral calcaneus (21,22). Stimulation for both arms
was applied at 20 Hz, as is typical for PTNS (35). For both DGNS
and PTNS subjects, starting from a low amplitude, current was
increased until the participant expressed discomfort, and then
reduced to a comfortable level, or a maximal level of 60 mA was
reached. Subsequently, stimulation was applied using that ampli-
tude for 30 min, at 20 Hz.
Participants completed a total of 12 stimulation sessions (12,17,35).
Our goal was to schedule sessions on consecutive weeks for the dura-
tion of participation. However, scheduling conflicts, holidays, and other
events led to variations in intrasession intervals across subjects. Partici-
pants were compensated for their time.
Patients completed a series of validated clinical surveys as outcome
measures at baseline, after 6 stimulation sessions, after 12 stimulation
sessions, and 6 weeks after the final session. At all survey intervals,
participants completed the full FSFI (36), the short-form 36-question
(SF-36) quality of life survey (37), and the 6-question American Uro-
logical Association Symptom Index (AUASI) bladder symptom index
(38). At the 6-week and later survey intervals participants also com-
pleted the one-question Patients’ Global Impression of Change (PGIC)
(39). All surveys were completed and stored through a secure online
portal (REDcap) (40).
Comparisons between FSFI, SF-36, AUASI, and PGIC scores
at different time points were analyzed with related-samples
Wilcoxon signed rank tests with a significance level of 0.05.
Tests were run with DGNS and PTNS arms separately as well as
pooled together. Where appropriate, values are presented as
mean  standard deviation.
RESULTS
Sixteen subjects were enrolled in the study (Fig. 1). Seven sub-
jects dropped out of the study during intervention, due to
scheduling conflicts (n = 6) and an adverse event (n = 1;
described below). Of the nine subjects that completed the study,
the average age was 46.2  14.5, with a minimum age of 23 and
maximum of 66 (Table 1). One subject who was enrolled but did
not receive stimulation did not complete the demographics
survey.
Stimulation was not always delivered in exact 1-week inter-
vals. The average interval between sessions was 12.5  10.3 days.
The stimulation current amplitude that was delivered ranged
from 2.5 to 60.0 mA. Stimulation was delivered at 24.3  18.6 mA
for DGNS subjects, and 60.0  0.0 mA for PTNS subjects.
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Table 1. Patient Demographics.
Category All enrolled participants PTNS completed DGNS completed
Total 16 3 6
Age (years) 40.9  15.0 37.3  19.1 50.7  11.0
BMI (kg/m2) 26.8  4.4 28.4  5.0 26.3  4.9
Race/Ethnicity
White 10 (67%) 2 (67%) 6 (100%)
Black 1 (7%) 1 (33%) 0 (0%)
Asian or Pacific Islander 1 (7%) 0 (0%) 0 (0%)
Other 3 (20%) 0 (0%) 0 (0%)
Relationship status
Single 2 (13%) 0 (0%) 1 (17%)
Nonmarried relationship 3 (20%) 1 (33%) 0 (0%)
Married 10 (67%) 2 (67%) 5 (83%)
On prescription antidepressant 6 (40%) 2 (67%) 3 (50%)
Baseline FSFI 17.1  5.0 15.2  5.3 15.5  4.6
Baseline SF-36 83.1  11.6 87.9  4.4 80.5  9.0



























Figure 2. Average total FSFI score for all subjects (PTNS and DGNS) at each sur-
vey time point. Error bars give standard error of the mean. Significant improve-
ment from baseline occurred at each time point. Individual icons are unique for
each participant, with PTNS participants indicated with stars and DGNS partici-
pants indicated with circles and squares. White, gray, and black shading inside of
each icon further distinguishes between different subjects. Within each study
week, icon order from left to right indicates study participation order (*p < 0.05;
**p < 0.01). [Color figure can be viewed at wileyonlinelibrary.com]
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All women began the study with an FSFI total score below the
clinical cut-off for diagnosing FSD (26.55) (41), with an average ini-
tial score of 15.3  4.8. Overall sexual function significantly
increased at 6, 12, and 18 weeks from baseline (Fig. 2, Table 2).
Three of the nine subjects (33.3%) reached an FSFI score above
the clinical cut-off for FSD, and another participant scored just
below the threshold (26.4). Four subjects (1 DGNS, 3 PTNS) had a
clinically relevant increase in their FSFI score, with an improve-
ment of at least 50%. Arousal and orgasm FSFI subscores had sig-
nificant improvements at 6, 12, and 18 weeks from baseline
(Fig. 3, Table 2) Lubrication FSFI subscores had a significant
improvement at 12 weeks over baseline (Fig. 3, Table 2). Each of
the other FSFI subscores (desire, satisfaction, and pain) had non-
significant increases in their scores (Fig. 3, Table 2).
Changes in FSFI scores were not related to variations in the
intervals between stimulation sessions. The FSFI percent increase
had no relationship with average stimulation session intervals at
12 weeks (y = −0.077x + 40.58, R2 = 0.0139, p = 0.78) or at
18 weeks (y = −0.1309x + 57.97, R2 = 0.026, p = 0.70).
Overall, participants perceived an improvement in sexual
function, as PGIC scores were 3.3  2.0 at 6 weeks (3.0 = “a little
better”), 4.0  1.9 at 12 weeks (4.0 = “somewhat better”), and
4.1  1.9 at 18 weeks. These scores are each significantly differ-
ent from a PGIC score of 1.0 (p = 0.018, p = 0.011, and p = 0.011,
respectively), which would indicate “no change or worse.” The
three women (2 PTNS, 1 DGNS) who achieved FSFI scores above
the FSD clinical cutoff scored either a 5 (“moderately better”) or
6 (“better”) at each time point. Overall quality of health scores
from the SF-36 remained generally stable across the study dura-
tion. The SF-36 category of role limitations due to physical
health improved from 88.9% pretreatment to 97.2% at the
18-week time point across all subjects. Also the SF-36 category
emotional well-being showed a significant worsening from
80.0% pretreatment to 74.2% at week 6 (p = 0.042) for DGNS
subjects. Participant’s bladder functioning, as scored by the
AUASI, did not show significant change across all subjects across
the study time points, except for the domain of nocturia. There
was a significant 25.0% reduction in nocturia symptoms
(p = 0.046) from baseline (1.78  1.30) to the 18-week time-
point (1.33  1.22).
Subjects were given the opportunity to refrain from answering
questions. The unanswered questions were scored as a 0, which
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Figure 3. Individual FSFI subdomain scores for all subjects. The pooled mean is given by the horizontal bar. Individual icons are unique for each participant, fol-
lowing the convention in Fig. 2. Within each study week, icon order from left to right indicates study participation order (*p < 0.05). [Color figure can be viewed
at wileyonlinelibrary.com]
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negatively affected FSFI scoring. Three DGNS subjects (blue/white
square, blue/gray square, and blue/black square in Figs. 2 and 3)
refrained from answering questions about pain. Two of those sub-
jects (blue/gray square and blue/black square) also refrained from
answering some of the questions about satisfaction in two sur-
veys. One of those subjects (blue/black square) also refrained
from answering some of the questions about lubrication in one
survey. One subject (red/black star) reported that between weeks
12 and 18 surveys, she was diagnosed with a severe pelvic
infection from Escherichia coli. She indicated that this unrelated
event would negatively impact her 18-week survey, as seen by
declines in her scores from weeks 12 to 18, particularly in
pain (Fig. 3).
One participant receiving PTNS withdrew from the study after
three sessions after feeling sciatic nerve pain during stimulation.
The subject had a history of sciatic pain. Aggravation reemerged
after both lowering the amplitude of current delivered and
switching the stimulation location to the alternate leg.
DISCUSSION
In this study, we demonstrate the feasibility of transcutaneous
stimulation as a treatment for genital arousal disorders in women.
Significant improvements were achieved in the areas of arousal,
lubrication, and orgasm (Fig. 3, Table 2), leading to overall better
sexual functioning (Fig. 2). These domains are each related to
genital arousal. Subjects reported the highest sexual functioning
at 12 weeks into the study, after having received all stimulation
sessions. A slight decrease in overall FSFI scores occurred at
18 weeks, after a 6-week washout period without stimulation,
suggesting that maintenance sessions may be beneficial. Main-
tenance sessions are common for patients receiving PTNS for
bladder symptoms, with patients receiving a stimulation session
every 2–4 weeks after the initial 12 weeks of therapy to maintain
the therapeutic benefits (42). The subjects in the PTNS arm had
a greater improvement in sexual functioning (Table 2), but the
imbalance of subjects in each arm makes it difficult to perform
any statistical comparisons. As 100% of PTNS subjects increased
their total FSFI score by at least 50%, compared to 16.7% of the
DGNS group, it is possible that PTNS is a more effective
treatment modality, although further studies with larger sample
sizes are needed. Two PTNS subjects commented that they
planned to purchase their own TENS equipment to continue
treatment at home after study completion.
Across all subjects, the average total of FSFI score increased
by 6.4 (Table 2). This increase is comparable to or greater than
recent clinical trials studying other treatments for women with
desire and/or arousal subtypes of FSD. In the BEGONIA trial
investigating FDA-approved flibanserin for hypoactive sexual
desire, the treatment group total FSFI score improved by 5.3
against the placebo group increase of 3.5 (8), while a study of
bremelanotide saw a total FSFI increase of 4.4 in the most
effective treatment group against a placebo increase of 1.9
(43). Clinical studies of neuromodulation, which presumably
would benefit genital arousal disorders over hypoactive sexual
desire, have reported a total FSFI score increase of 6.5 in a
group of patients receiving PTNS for OAB (30) and 4.3 in a
group of patients with SNM implants (44), with other SNM and
PTNS neuromodulation studies reporting even smaller FSFI
increases (range: 2.1–3.3) (24–27,29). That our FSFI increase
was comparable to or higher than neuromodulation studies
using invasive stimulation electrodes suggests that noninva-
sive transcutaneous stimulation can yield effective results. A
larger, controlled study is needed to verify that we did not
have an overall placebo effect higher than those reported in
the flibanserin and bremelanotide studies. The nonsignificant
increases in nongenital arousal related FSFI subdomains (desire,
satisfaction, and pain; Fig. 3, Table 2) could indicate that stimula-
tion led to benefits in these areas, either directly or indirectly
through improvements in genital arousal, or those increases
may relate to any general placebo effects that occurred in our
study.
These results provide further evidence that the improve-
ments to sexual functioning seen in neuromodulation studies
for bladder dysfunction are a direct result of the therapy, as
opposed to a secondary result from treated bladder symptoms.
Peripheral nerve stimulation could be used as a clinical tool to
treat women with genital arousal deficiencies. Women who
may benefit from this treatment have a variety of potential
underlying conditions, including diabetes-related complica-
tions, neurological conditions such as multiple sclerosis and
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Table 2. Average FSFI Scores Across All Subjects As Well As Across Two Subject Groups, With Standard Deviation in ().
Desire Arousal Lubrication Orgasm Satisfaction Pain Total
All (n = 9)
Baseline 2.3 (1.0) 2.2 (0.9) 2.8 (1.5) 2.7 (1.7) 2.7 (1.1) 3.3 (1.8) 15.3 (4.8)
6 weeks 2.7 (1.3) 3.3 (1.3)* 4.1 (1.7) 3.8 (1.7)* 3.8 (1.8) 4.6 (1.8) 20.3 (7.8)*
12 weeks 3.0 (1.2) 3.6 (1.4)* 3.7 (1.5)* 3.8 (1.5)* 3.8 (1.7) 4.9 (2.3) 21.7 (7.5)*
18 weeks 2.7 (1.3) 4.0 (1.4)* 3.8 (1.5) 4.4 (1.6)* 4.3 (1.8) 4.1 (2.1) 21.3 (7.1)*
DGNS (n = 6)
Baseline 2.3 (1.0) 2.3 (1.0) 2.9 (1.6) 2.7 (2.0) 2.6 (1.4) 3.5 (2.3) 15.2 (5.3)
6 weeks 2.0 (1.0) 2.8 (1.0) 3.3 (2.1) 3.8 (1.6) 3.2 (2.1) 4.5 (2.3) 17.4 (6.6)
12 weeks 2.5 (1.2) 3.0 (1.1) 3.6 (1.4)* 3.5 (1.6) 3.1 (1.7) 4.5 (2.2) 18.7 (6.9)*
18 weeks 2.2 (0.8) 3.7 (1.4)* 4.1 (1.2) 4.1 (1.7) 3.5 (1.9) 4.1 (2.6) 18.8 (5.4)*
PTNS (n = 3)
Baseline 2.4 (1.2) 2.1 (0.9) 2.5 (1.5) 2.5 (1.2) 2.9 (0.2) 3.1 (1.3) 15.5 (4.6)
6 weeks 4.0 (0.7) 4.4 (1.5) 4.4 (2.3) 3.9 (2.3) 4.7 (1.0) 4.7 (1.4) 26.0 (7.8)
12 weeks 4.0 (0.3) 4.9 (0.9) 4.1 (2.0) 4.3 (1.3) 5.2 (0.0) 5.3 (0.6) 27.8 (4.8)
18 weeks 3.8 (1.5) 4.6 (1.5) 3.4 (2.3) 4.9 (1.5) 5.3 (1.2) 4.1 (2.2) 26.2 (8.6)
*Statistical significance (p < 0.05), as compared between each study time point and baseline.
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spinal cord injury, and side-effects of hormonal changes,
trauma, and even childbirth (4,5,45,46). A potential mechanism
in the observed improvements in genital arousal in our study is
an increase in pelvic blood flow, as has been modeled by pre-
clinical studies investigating similar stimulation techniques
(47,48), however more research is needed.
An important limitation in this study is the lack of a control. As
the results are based on patient-reported outcomes, the impact of
a placebo effect could be considerable. Neither the researchers nor
the subjects were blinded. There were challenges in recruitment for
the study, but more notably in retention. Two primary factors were
a need for weekly stimulation sessions during normal business
hours and the location of the clinical research center, which
required a car or bus to reach. Six of the seven subjects who
discontinued the study were in the PTNS arm (Fig. 1), leading
to an unequal distribution of subjects. Once enrolled, it was
also difficult to schedule subjects every week, so most did not
complete the study in the expected 18 weeks. This was due to
both patient scheduling conflicts as well as clinician availabil-
ity. Although the stimulation session intervals often differed
from standard PTNS clinical practice for bladder symptoms, no
effect on our results was observed. Finally, skin-surface trans-
cutaneous stimulation was utilized, and though it has been
shown to be effective clinically (15,49,50), it is less specific than
percutaneous needles.
Future studies with sham or placebo controls, as have been
completed for bladder care, are necessary to confirm the efficacy
of this treatment modality (17). In addition, percutaneous stimula-
tion could be used for more accurate recruitment of target
nerves.
CONCLUSION
This study provides further evidence that improvements seen
in the sexual functioning of women receiving neuromodulation
treatment for bladder dysfunction were independent of improve-
ments in bladder symptoms, and that stimulation can have a
direct impact on sexual arousal. Improvements were primarily
seen in genital arousal components of sexual functioning, includ-
ing lubrication, arousal, and orgasm. Thus, this pilot study demon-
strates the feasibility of using transcutaneous neuromodulation of
peripheral nerves to treat symptoms of FSD.
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COMMENT
This is an interesting pilot study looking at non-invasive neuromo-
dulation for female sexual dysfunction in women without lower uri-
nary tract conditions. It follows work done years ago, by our group
and others, that demonstrated improved sexual function in women
undergoing neuromodulation for urologic conditions. However, a
drawback of the prior studies was an inability to determine if sexual
function improved de novo from neuromodulation or as a result of
less bother from the urinary condition that drove patients to seek
treatment. The current study shows a clear benefit of neuromodula-
tion to arousal, orgasm and possibly lubrication, opening the door
for further investigation into the use of neuromodulation for female
sexual dysfunction - a condition that has been challenging to treat
with few available therapies.
Bradley Gill, MD, MS
Cleveland, OH, USA
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